Anti-RUNX1 Polyclonal Antibody for WB, ELISA - Q01196

Core Product Specifications and Parameters

Biological Background: RUNX1 Function and Localization

• RUNX1 (Runt-related transcription factor 1), also known as AML1 or CBFA2, is a member of the RUNX family that plays a pivotal role in hematopoiesis and immune cell development. It encodes multiple isoforms, including AML-1G and AML-1L, which differ in DNA-binding affinity and functional activities.
• RUNX1 forms a heterodimeric core-binding factor (CBF) complex with CBFB, which binds to the consensus sequence 5'-TGTGGT-3' in the regulatory regions of target genes, thereby modulating their transcription. This complex is essential for the development of normal hematopoiesis. Related references: PMID:17431401
• It transactivates key promoters such as IL-3 and BLK through synergistic interactions with transcription factors ELF4 and ELF2, respectively. Related references: PMID:10207087 PMID:14970218
• In T-cell development, RUNX1 participates in lineage commitment by repressing ZBTB7B to allow cytotoxic CD8+ T-cell differentiation, and it controls regulatory T-cell (Treg) anergy and suppressive function by associating with FOXP3, modulating IL2, IFNG, and CTLA4 expression. Related references: PMID:17377532
• RUNX1 is predominantly localized in the nucleus, consistent with its role as a transcription factor. It is widely expressed across tissues, with the highest levels in thymus, bone marrow, and peripheral blood, but absent from brain and heart.
• The protein is subject to multiple post-translational modifications including acetylation, methylation, and phosphorylation, which regulate its activity. It is classified as a proto-oncogene, and chromosomal rearrangements involving RUNX1 are associated with various leukemias.
• Isoform AML-1G exhibits higher DNA-binding affinity and is more effective in target gene binding, whereas AML-1L can interfere with the transactivation activity of RUNX1, providing nuanced regulation.

Experimental Guidance and Technical Tips

• The immunogen corresponds to a sequence within the N-terminal half of RUNX1 (amino acids 150–250), which includes regions that may be conserved across species. For Western blot, expect a band at approximately 49 kDa; additional bands may represent isoforms or post-translationally modified forms. Validate in the relevant sample system using appropriate controls.
• For ELISA, consider using this polyclonal antibody as a capture or detection reagent in direct or sandwich formats. Optimization of coating concentration and blocking conditions is recommended.
• Cross-reactivity is stated for human, mouse, and rat RUNX1; however, verify sequence alignment of the immunogen region to ensure expected reactivity in your experimental model.
• As a polyclonal antibody, lot-to-lot variability can occur. Include positive and negative controls in each experiment to confirm consistent performance.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers diagnostic manufacturers and research labs a streamlined, one-stop access to IVD raw materials, with expertise spanning from concept to clinic. This anti-RUNX1 polyclonal antibody supports investigations into hematopoiesis, leukemia, and immune regulation, and we complement it with validated antibody pairs, bulk ancillary reagents, and customized sourcing services for rare targets. Let us help you accelerate your assay development with reliable, high-quality raw materials.